{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:15:32Z","timestamp":1791465332029,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10510032120003"],"award-info":[{"award-number":["10510032120003"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tau-PET is a diagnostic tool with high sensitivity and specificity for discriminating Alzheimer\u2019s disease (AD) dementia from other neurodegenerative disorders in well-controlled research environments. The role of tau-PET in real-world clinical practice, however, remains to be established. The aim of the TAP-TAU study is therefore to investigate the impact of tau-PET in clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>TAP-TAU is a prospective, longitudinal multi-center study in 300 patients (\u2265\u200950 years old) with mild cognitive impairment or mild dementia across five Dutch memory clinics. Patients are eligible if diagnostic certainty is &lt;\u200985% after routine dementia screening and if the differential diagnosis includes AD. More specifically, we will include patients who (i) are suspected of having mixed pathology (e.g., AD and vascular pathology), (ii) have an atypical clinical presentation, and\/or (iii) show conflicting or inconclusive outcomes on other tests (e.g., magnetic resonance imaging or cerebrospinal fluid). Participants will undergo a [<jats:sup>18<\/jats:sup>F]flortaucipir tau-PET scan, blood-based biomarker sampling, and fill out questionnaires on patient reported outcomes and experiences. The primary outcomes are change (pre- versus post- tau-PET) in diagnosis, diagnostic certainty, patient management and patient anxiety and uncertainty. Secondary outcome measures are head-to-head comparisons between tau-PET and less invasive and lower cost diagnostic tools such as novel blood-based biomarkers and artificial intelligence-based classifiers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>TAP-TAU has been approved by the Medical Ethics Committee of the Amsterdam UMC. The first participant is expected to be included in October 2024.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In TAP-TAU, we will investigate the added clinical value of tau-PET in a real-world clinical setting, including memory clinic patients with diagnostic uncertainty after routine work-up. Findings of our study may contribute to recommendations regarding which patients would benefit most from assessment with tau-PET. This study is timely in the dawning era of disease modifying treatments as an accurate etiological diagnosis becomes increasingly important.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This trial is registered and authorized on December 21st, 2023 in EU Clinical Trials with registration number 2023-505430-10-00.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-024-01588-4","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T06:02:27Z","timestamp":1729317747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study"],"prefix":"10.1186","volume":"16","author":[{"given":"Marie R.","family":"Vermeiren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Somsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Luurtsema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fransje E.","family":"Reesink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas A.","family":"Verwey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Hempenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelleke","family":"Tolboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert Jan","family":"Biessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Matthijs","family":"Biesbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike W.","family":"Vernooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie E. M.","family":"Veldhuijzen van Zanten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harro","family":"Seelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Coomans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afina W.","family":"Lemstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argonde C.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie N. C.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsmarieke","family":"van de Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"issue":"10043","key":"1588_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet. 2016;388(10043):505\u201317.","journal-title":"Lancet"},{"key":"1588_CR2","doi-asserted-by":"crossref","unstructured":"Ch\u00e9telat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias. The Lancet Neurology. Volume 19. Lancet Publishing Group; 2020. pp. 951\u201362.","DOI":"10.1016\/S1474-4422(20)30314-8"},{"key":"1588_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.nicl.2018.05.024","volume":"19","author":"NME Scheltens","year":"2018","unstructured":"Scheltens NME, van der Weijden K, Adriaanse SM, van Assema D, Oomen PP, Krudop WA, et al. Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer\u2019s disease. Neuroimage Clin. 2018;19:625\u201332.","journal-title":"Neuroimage Clin"},{"issue":"4","key":"1588_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease centers, 2005\u20132010. J Neuropathol Exp Neurol. 2012;71(4):266\u201373.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"10","key":"1588_CR5","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/jamaneurol.2020.1741","volume":"77","author":"S Karanth","year":"2020","unstructured":"Karanth S, Nelson PT, Katsumata Y, Kryscio RJ, Schmitt FA, Fardo DW, et al. Prevalence and clinical phenotype of Quadruple misfolded proteins in older adults. JAMA Neurol. 2020;77(10):1299\u2013307.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1588_CR6","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/brain\/awaa438","volume":"144","author":"JL Robinson","year":"2021","unstructured":"Robinson JL, Richardson H, Xie SX, Suh E, Van Deerlin VM, Alfaro B, et al. The development and convergence of co-pathologies in Alzheimer\u2019s disease. Brain. 2021;144(3):953\u201362.","journal-title":"Brain"},{"issue":"4","key":"1588_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00002093-200210000-00001","volume":"16","author":"WW Barker","year":"2002","unstructured":"Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203\u201312.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"7","key":"1588_CR8","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/brain\/awab099","volume":"144","author":"S Spina","year":"2021","unstructured":"Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer\u2019s disease. Brain. 2021;144(7):2186\u201398.","journal-title":"Brain"},{"key":"1588_CR9","doi-asserted-by":"crossref","unstructured":"Levin J, Baiardi S, Quadalti C, Rossi M, Mammana A, V\u00f6glein J, et al. \u03b1-Synuclein seed amplification assay detects Lewy body co\u2010pathology in autosomal dominant Alzheimer\u2019s disease late in the disease course and dependent on Lewy pathology burden. Alzheimer\u2019s & Dementia. 2024;20(6):4351\u20134365.","DOI":"10.1002\/alz.13818"},{"issue":"19","key":"1588_CR10","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM, et al. Prevalence of amyloid PET positivity in dementia syndromes. JAMA. 2015;313(19):1939.","journal-title":"JAMA"},{"issue":"19","key":"1588_CR11","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924\u201338.","journal-title":"JAMA"},{"issue":"226","key":"1588_CR12","doi-asserted-by":"publisher","first-page":"226ra30","DOI":"10.1126\/scitranslmed.3007901","volume":"6","author":"AM Fagan","year":"2014","unstructured":"Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer\u2019s disease. Sci Transl Med. 2014;6(226):226ra30.","journal-title":"Sci Transl Med"},{"key":"1588_CR13","doi-asserted-by":"crossref","unstructured":"Jack CR, Holtzman DM. Biomarker modeling of alzheimer\u2019s disease. Volume 80. Neuron. Cell; 2013. pp. 1347\u201358.","DOI":"10.1016\/j.neuron.2013.12.003"},{"key":"1588_CR14","doi-asserted-by":"crossref","unstructured":"Pichet Binette A, Franzmeier N, Spotorno N, Ewers M, Brendel M, Biel D, et al. Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer. Nat Commun. 2022;13(1):6635.","DOI":"10.1002\/alz.065080"},{"key":"1588_CR15","doi-asserted-by":"crossref","unstructured":"Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer\u2019s disease. Sci Adv. 2020;6(16):eaaz2387.","DOI":"10.1126\/sciadv.aaz2387"},{"issue":"19","key":"1588_CR16","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939\u201349.","journal-title":"JAMA"},{"issue":"2","key":"1588_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of phosphorylated tau biomarkers with amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. 2023;80(2):188.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1588_CR18","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/brain\/awac329","volume":"146","author":"C Groot","year":"2023","unstructured":"Groot C, Smith R, Stomrud E, Binette AP, Leuzy A, Wuestefeld A, et al. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals. Brain. 2023;146(4):1580\u201391.","journal-title":"Brain"},{"issue":"12","key":"1588_CR19","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.neurobiolaging.2008.02.007","volume":"30","author":"FH Bouwman","year":"2009","unstructured":"Bouwman FH, Schoonenboom NSM, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, et al. CSF biomarker levels in early and late onset Alzheimer\u2019s disease. Neurobiol Aging. 2009;30(12):1895\u2013901.","journal-title":"Neurobiol Aging"},{"key":"1588_CR20","doi-asserted-by":"crossref","unstructured":"Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S, et al. Tau PET correlates with different Alzheimer\u2019s disease-related features compared to CSF and plasma p\u2010tau biomarkers. EMBO Mol Med. 2021;13(8):e14398.","DOI":"10.15252\/emmm.202114398"},{"key":"1588_CR21","unstructured":"Rabinovici GD, Knopman D, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O et al. Revised Criteria for Diagnosis and Staging of Alzheimer\u2019s Disease: Alzheimer\u2019s Association Workgroup. [cited 2024 May 2]; https:\/\/aaic.alz.org\/diagnostic-criteria.asp"},{"issue":"7","key":"1588_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron Emission Tomography Imaging with [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 2020;77(7):829.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1588_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2019.09.079","volume":"16","author":"VJ Lowe","year":"2020","unstructured":"Lowe VJ, Lundt ES, Albertson SM, Min HK, Fang P, Przybelski SA, et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2020;16(3):561\u201371.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"1588_CR24","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awaa276","volume":"143","author":"DN Soleimani-Meigooni","year":"2020","unstructured":"Soleimani-Meigooni DN, Iaccarino L, La Joie R, Baker S, Bourakova V, Boxer AL, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer\u2019s disease and other neurodegenerative diseases. Brain. 2020;143(11):3477\u201394.","journal-title":"Brain"},{"issue":"8","key":"1588_CR25","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/brain\/awab120","volume":"144","author":"SY Yap","year":"2021","unstructured":"Yap SY, Frias B, Wren MC, Sch\u00f6ll M, Fox NC, \u00c5rstad E, et al. Discriminatory ability of next-generation tau PET tracers for Alzheimer\u2019s disease. Brain. 2021;144(8):2284\u201390.","journal-title":"Brain"},{"key":"1588_CR26","doi-asserted-by":"crossref","unstructured":"Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun 2016;4(1).","DOI":"10.1186\/s40478-016-0315-6"},{"issue":"11","key":"1588_CR27","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M, Strandberg O, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA - J Am Med Association. 2018;320(11):1151\u201362.","journal-title":"JAMA - J Am Med Association"},{"issue":"10","key":"1588_CR28","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1093\/brain\/awz268","volume":"142","author":"CR Jack","year":"2019","unstructured":"Jack CR, Wiste HJ, Botha H, Weigand SD, Therneau TM, Knopman DS, et al. The bivariate distribution of amyloid-\u03b2 and tau: relationship with established neurocognitive clinical syndromes. Brain. 2019;142(10):3230\u201342.","journal-title":"Brain"},{"key":"1588_CR29","doi-asserted-by":"crossref","unstructured":"Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143(9):2818\u20132830.","DOI":"10.1093\/brain\/awaa180"},{"issue":"8","key":"1588_CR30","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, et al. Diagnostic performance of RO948 F 18 Tau Positron Emission Tomography in the differentiation of Alzheimer Disease from Other Neurodegenerative disorders. JAMA Neurol. 2020;77(8):955\u201365.","journal-title":"JAMA Neurol"},{"issue":"7","key":"1588_CR31","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s00259-021-05401-4","volume":"48","author":"A Leuzy","year":"2021","unstructured":"Leuzy A, Pascoal TA, Strandberg O, Insel P, Smith R, Mattsson-Carlgren N, et al. A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. Eur J Nucl Med Mol Imaging. 2021;48(7):2295\u2013305.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Pt 5","key":"1588_CR32","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139(Pt 5):1551\u201367.","journal-title":"Brain"},{"issue":"1","key":"1588_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110\u20139.","journal-title":"Ann Neurol"},{"key":"1588_CR34","doi-asserted-by":"crossref","unstructured":"Macedo AC, Therriault J, Tissot C, Fernandez-Arias J, Ferreira PCL, Vitali P et al. Predicting functional decline in aging and Alzheimer\u2019s disease with PET-based Braak staging. Brain Commun. 2024;6(2).","DOI":"10.1093\/braincomms\/fcae043"},{"key":"1588_CR35","doi-asserted-by":"crossref","unstructured":"Tissot C, Therriault J, Pascoal TA, Chamoun M, Lussier FZ, Savard M et al. Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2021;7(1).","DOI":"10.1002\/trc2.12154"},{"issue":"6","key":"1588_CR36","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","volume":"92","author":"R Ossenkoppele","year":"2019","unstructured":"Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, et al. Associations between tau, A\u03b2, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601\u201312.","journal-title":"Neurology"},{"issue":"5","key":"1588_CR37","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1212\/WNL.0000000000011270","volume":"96","author":"R La Joie","year":"2021","unstructured":"La Joie R, Visani AV, Lesman-Segev OH, Baker SL, Edwards L, Iaccarino L, et al. Association of APOE4 and clinical variability in Alzheimer Disease with the pattern of tau- and Amyloid-PET. Neurology. 2021;96(5):e650\u201361.","journal-title":"Neurology"},{"key":"1588_CR38","doi-asserted-by":"crossref","unstructured":"Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. The Lancet Neurology. Volume 21. Elsevier Ltd; 2022. pp. 726\u201334.","DOI":"10.1016\/S1474-4422(22)00168-5"},{"issue":"7","key":"1588_CR39","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00259-020-05118-w","volume":"48","author":"EE Wolters","year":"2021","unstructured":"Wolters EE, Dodich A, Boccardi M, Corre J, Drzezga A, Hansson O, et al. Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase biomarker development framework. Eur J Nucl Med Mol Imaging. 2021;48(7):2097\u2013109.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1588_CR40","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","volume":"75","author":"A De Wilde","year":"2018","unstructured":"De Wilde A, Van Der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 2018;75(9):1062\u201370.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1588_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-016-0228-4","volume":"9","author":"MD Zwan","year":"2017","unstructured":"Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FRJ, et al. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9(1):2.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1588_CR42","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","volume":"9","author":"R Ossenkoppele","year":"2013","unstructured":"Ossenkoppele R, Prins ND, Pijnenburg YAL, Lemstra AW, Van Der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer\u2019s Dement. 2013;9(4):414\u201321.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"1588_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40658-023-00588-x","volume":"10","author":"M Shekari","year":"2023","unstructured":"Shekari M, Verwer EE, Yaqub M, Daamen M, Buckley C, Frisoni GB, et al. Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan. EJNMMI Phys. 2023;10(1):68.","journal-title":"EJNMMI Phys"},{"key":"1588_CR44","doi-asserted-by":"crossref","unstructured":"Coomans EM, de Koning LA, Rikken RM, Verfaillie SCJ, Visser D, den Braber A et al. Performance of a [ 18 F]flortaucipir PET visual read Method across the Alzheimer Disease Continuum and in Dementia with Lewy Bodies. Neurology. 2023;101(19).","DOI":"10.1212\/WNL.0000000000207794"},{"issue":"2","key":"1588_CR45","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000073003","volume":"6","author":"AK van der Bij","year":"2003","unstructured":"van der Bij AK, de Weerd S, Cikot RJLM, Steegers EAP, Braspenning JCC. Validation of the Dutch short form of the State Scale of the Spielberger state-trait anxiety inventory: considerations for usage in screening outcomes. Public Health Genomics. 2003;6(2):84\u20137.","journal-title":"Public Health Genomics"},{"issue":"3","key":"1588_CR46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.2044-8260.1992.tb00997.x","volume":"31","author":"TM Marteau","year":"1992","unstructured":"Marteau TM, Bekker H. The development of a six-item short\u2010form of the state scale of the Spielberger State\u2014trait anxiety inventory (STAI). Br J Clin Psychol. 1992;31(3):301\u20136.","journal-title":"Br J Clin Psychol"},{"issue":"2","key":"1588_CR47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00006199-198803000-00009","volume":"37","author":"MH Mishel","year":"1988","unstructured":"Mishel MH, Braden CJ. Finding meaning: antecedents of uncertainty in illness. Nurs Res. 1988;37(2):98\u2013103.","journal-title":"Nurs Res"},{"key":"1588_CR48","doi-asserted-by":"crossref","unstructured":"Nyman SR, Casey C, Polman R. Psychometric properties of the ICECAP-O Quality of Life Measurement Tool when Self-reported by community-dwelling older people with mild and moderate dementia. Alzheimer Dis Assoc Disord. 2021;35(4):356\u20139.","DOI":"10.1097\/WAD.0000000000000430"},{"issue":"15","key":"1588_CR49","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1016\/j.ejca.2010.06.118","volume":"46","author":"JI Arraras","year":"2010","unstructured":"Arraras JI, Greimel E, Sezer O, Chie WC, Bergenmar M, Costantini A, et al. An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients. Eur J Cancer. 2010;46(15):2726\u201338.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1588_CR50","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0272989X03256005","volume":"23","author":"JC Brehaut","year":"2003","unstructured":"Brehaut JC, O\u2019Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, et al. Validation of a decision regret scale. Med Decis Mak. 2003;23(4):281\u201392.","journal-title":"Med Decis Mak"},{"key":"1588_CR51","doi-asserted-by":"crossref","unstructured":"Altomare D, Caprioglio C, Assal F, Allali G, Mendes A, Ribaldi F, et al. Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. Eur J Nucl Med Mol Imaging. 2021;48:2200\u20132211.","DOI":"10.1007\/s00259-021-05246-x"},{"issue":"6","key":"1588_CR52","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jamaneurol.2023.0997","volume":"80","author":"D Altomare","year":"2023","unstructured":"Altomare D, Barkhof F, Caprioglio C, Collij LE, Scheltens P, Lopes Alves I, et al. Clinical effect of early vs late amyloid Positron Emission Tomography in Memory Clinic patients: the AMYPAD-DPMS Randomized Clinical Trial. JAMA Neurol. 2023;80(6):548\u201357.","journal-title":"JAMA Neurol"},{"key":"1588_CR53","doi-asserted-by":"crossref","unstructured":"Smith R, H\u00e4gerstr\u00f6m D, Pawlik D, Klein G, J\u00f6gi J, Ohlsson T, et al. Clinical utility of tau Positron Emission Tomography in the diagnostic workup of patients with cognitive symptoms. JAMA Neurol. 2023;1;80(7):749\u2013756.","DOI":"10.1001\/jamaneurol.2023.1323"},{"issue":"13","key":"1588_CR54","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of Amyloid Positron Emission Tomography with subsequent change in Clinical Management among Medicare Beneficiaries with mild cognitive impairment or dementia. JAMA - J Am Med Association. 2019;321(13):1286\u201394.","journal-title":"JAMA - J Am Med Association"},{"issue":"5","key":"1588_CR55","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/alz.12846","volume":"19","author":"IS van Maurik","year":"2023","unstructured":"van Maurik IS, Broulikova HM, Mank A, Bakker ED, de Wilde A, Bouwman FH, et al. A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting. Alzheimer\u2019s Dement. 2023;19(5):2006\u201313.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1588_CR56","doi-asserted-by":"crossref","unstructured":"Shimohama S, Tezuka T, Takahata K, Bun S, Tabuchi H, Seki M et al. Impact of amyloid and tau PET on changes in diagnosis and patient management. Neurology. 2023;100(3).","DOI":"10.1212\/WNL.0000000000201389"},{"key":"1588_CR57","doi-asserted-by":"crossref","unstructured":"Josephs KA, Tosakulwong N, Weigand SD, Graff-Radford J, Schwarz CG, Senjem ML et al. Flortaucipir PET uncovers relationships between tau and amyloid-\u03b2 in primary age\u2013related tauopathy and Alzheimer\u2019s disease. Sci Transl Med. 2024;16(757).","DOI":"10.1126\/scitranslmed.ado8076"},{"issue":"7","key":"1588_CR58","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1007\/s00259-020-05120-2","volume":"48","author":"M Boccardi","year":"2021","unstructured":"Boccardi M, Dodich A, Albanese E, Gayet-Ageron A, Festari C, Ashton NJ, et al. The strategic biomarker roadmap for the validation of Alzheimer\u2019s diagnostic biomarkers: methodological update. Eur J Nucl Med Mol Imaging. 2021;48(7):2070\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1588_CR59","doi-asserted-by":"crossref","unstructured":"Rabinovici GD, Knopman D, Arbizu J, Donohoe STL, Hansson KJ. O, 2024 AUC for amyloid and tau PET: updated appropriate use criteria for amyloid and tau PET in Alzheimer\u2019s Disease. Butler Hospital Memory and Aging Program. 2024;17.","DOI":"10.1002\/alz.078912"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01588-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01588-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01588-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T18:03:40Z","timestamp":1729361020000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01588-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1588"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01588-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,19]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TAP-TAU study is in accordance with the WMA Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects 2013 and has been reviewed by the Medical Ethics Committee from the Amsterdam University Medical Center. Approval was obtained December 21st, 2023. Before participation, all participants will sign written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}